财联社·2025-10-09 01:56Core Insights - The Hong Kong IPO market experienced significant growth in the first three quarters of 2025, leading globally with 68 new listings and total fundraising of HKD 182.45 billion, representing a 51% and 227% increase year-on-year respectively [1][4] - The high demand for new shares is evident, with 98% of new stocks being oversubscribed and 86% having oversubscription multiples exceeding 20 times, doubling from the previous year [2][4] - The current market activity is characterized by healthy growth following regulatory changes that ended the era of high-leverage IPO subscriptions, shifting the focus to intrinsic value recognition and natural capital inflow [4][8] New Share Subscription Trends - In the first three quarters of 2025, 15 new stocks had oversubscription multiples exceeding 1,000 times, accounting for nearly 23% of new listings, with the highest being Daheng Technology at 7,558.40 times [2][3] - The pharmaceutical and durable consumer goods sectors saw the most interest, with several biotech firms achieving significant oversubscription rates, indicating strong investor confidence in innovative drug companies [2][3] Market Performance Metrics - The first-day IPO failure rate dropped to 24%, the lowest in nine years, with an average first-day return of 28%, a substantial increase from 10.82% in the previous year [5][6] - Notably, large IPOs performed exceptionally well, with companies like Ningde Times seeing a first-day increase of 16% and cumulative gains exceeding 87% by September 30 [7] Policy and Market Dynamics - The surge in the IPO market is attributed to a combination of policy benefits, ample liquidity, and industry upgrades, with regulatory measures simplifying the listing process and enhancing market attractiveness [8][9] - The Hong Kong Stock Exchange has received 348 listing applications as of October 5, 2025, with ongoing efforts to optimize regulations and attract more overseas companies [8][9] Industry Structure and Appeal - The IPO landscape in Hong Kong is driven by a dual focus on technology and consumer sectors, with the medical and pharmaceutical industries leading in the number of listings, while manufacturing accounted for over 30% of fundraising [9]